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cross-sectional, ecological study of health system response 
in the Americas
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Summary
Background Disorders affecting mental health are highly prevalent, can be disabling, and are associated with 
substantial premature mortality. Yet national health system responses are frequently under-resourced, inefficient, and 
ineffective, leading to an imbalance between disease burden and health expenditures. We estimated the disease 
burden in the Americas caused by disorders affecting mental health. This measure was adjusted to include mental, 
neurological, and behavioural disorders that are frequently not included in estimates of mental health burden. We 
propose a framework for assessing the imbalance between disease burden and health expenditures.
Methods In this cross-sectional, ecological study, we extracted disaggregated disease burden data from the Global 
Health Data Exchange to produce country-level estimates for the proportion of total disease burden attributable to 
mental disorders, neurological disorders, substance use disorders, and self-harm (MNSS) in the Americas. We 
collated data from the WHO Assessment Instrument for Mental Health Systems and the WHO Mental Health Atlas 
on country-level mental health spending as a proportion of total government health expenditures, and of psychiatric 
hospital spending as a proportion of mental health expenditures. We used a metric capturing the imbalance between 
disease burden and mental health expenditures, and modelled the association between this imbalance and real 
(ie, adjusted for purchasing power parity) gross domestic product (GDP).
Findings Data were collected from July 1, 2016, to March 1, 2017. MNSS comprised 19% of total disability-adjusted life-
years in the Americas in 2015. Median spending on mental health was 2·4% (IQR 1·3–4·1) of government health 
spending, and median allocation to psychiatric hospitals was 80% (52–92). This spending represented an imbalance 
in the ratio between disease burden and efficiently allocated spending, ranging from 3:1 in Canada and the USA to 
435:1 in Haiti, with a median of 32:1 (12–170). Mental health expenditure as a proportion of government health 
spending was positively associated with real GDP (β=0·68 [95% CI 0·24–1·13], p=0·0036), while the proportion 
allocated to psychiatric hospitals (β=–0·5 [–0·79 to –0·22], p=0·0012) and the imbalance in efficiently allocated 
spending (β=–1·38 [–1·97 to –0·78], p=0·0001) were both inversely associated with real GDP. All estimated coefficients 
were significantly different from zero at the 0·005 level.
Interpretation A striking imbalance exists between government spending on mental health and the related disease 
burden in the Americas, which disproportionately affects low-income countries and is likely to result in 
undertreatment, increased avoidable disability and mortality, decreased national economic output, and increased 
household-level health spending.
Funding Weatherhead Center for International Affairs, Harvard University.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
An epidemiological transition has largely shifted the 
global burden of disease from communicable, maternal, 
childhood, and nutritional disorders to non-communicable 
diseases (NCDs).1,2 Mental health disorders represent a 
particularly complex challenge given their high prevalence 
and disability burden, estimated as the highest among 
NCDs.3–6 Yet, pervasive stigma, outdated practices, and 
organisational fragmentation still result in woefully 
inadequate responses by health systems to mental 
illness.7,8 Further, traditional approaches to measuring the 
disease burden of mental health problems have led to 
underestimates because of methodological constraints, 
including arbitrary separation between psychiatric and 
neurological disorders, consideration of self-harm as a 
category outside mental illness, conflation of painful 
somatisation disorders with musculoskeletal disorders, 
exclusion of personality disorders, and inadequate 
consideration of the contribution of mental illness to 
excess deaths.6
The aim of this study was to estimate the disease 
burden attributable to disorders affecting mental health 
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in the 35 countries in the WHO Region of the Americas, 
accounting for biases affecting previous estimates, and to 
analyse how expenditures in mental health services vary 
in relation to national economic output, as measured by 
real (ie, adjusted for purchasing power parity) gross 
domestic product (GDP) per capita.
Methods
Study design and data sources
In this cross-sectional, ecological study, we extracted 2015 
data published in October, 2016, and accessed online on 
Jan 1, 2017, for the WHO Region of the Americas on 
years lived with disability (YLD) and disability-adjusted 
life-years (DALYs), including country-age-sex-specific 
numbers, from the Global Health Data Exchange.9 
We then re-estimated the burden following the frame-
work described by Vigo et al,6 in 2016, which partially 
rectifies current underestimates by aggregating the 
burden of mental, neurological, and substance use 
disorders, and self-harm (MNSS). We included specific 
neurological conditions, self-harm and suicide, and 
an estimation for somatic symptom disorder with 
prominent pain, as described elsewhere.6 For the 
included neurological disorders (Alzheimer’s disease, 
epilepsy, tension-type headache, and migraine), we 
followed the approach of WHO, systematically adding 
specific neuro logical disorders to mental burden 
aggregations,10,11 the Disease Control Priorities Group,12 
and some Global Burden of Disease Study (GBD) 
publications,13,14 among others. The resulting estimates 
have advantages and limitations that are highlighted in 
the discussion.2,5,6,9
We obtained a set of spending and allocation estimates 
by collating the latest data available through the 
Pan American Health Organization and published in 
the Mental Health Atlas15 and the WHO Assessment 
Instrument for Mental Health Systems.16 When data 
were missing, we supplemented with additional 
available country-level data (resulting in a range of 
expenditure data from 2009 to 2015).17–22 For countries 
with unavailable data for either spending on mental 
health or on psychiatric hospitals, we imputed the 
median regional value. Four countries were missing 
both expenditure datapoints (Colombia, Cuba, 
Bahamas, and Grenada), and one country had no 
burden of disease data (St Kitts and Nevis). We treated 
them as missing at random and dropped them from the 
analysis. We also obtained 2015 real GDP per capita 
from the International Monetary Fund’s World 
Economic Outlook Database.23
Statistical analysis
Based on data for 30 countries we obtained a, proportion 
of total DALYs attributable to MNSS; b, proportion of 
total DALYs attributable to schizophrenia; c, proportion 
of DALYs attributable to schizophrenia corresponding to 
Research in context
Evidence before this study
The WHO Mental Health Atlas project, launched in 2001, 
and the WHO Assessment Instrument for Mental Health 
Systems, introduced in 2007, collect mental health systems 
data for the Americas and other regions, including 
government expenditures on mental health and expenditures 
allocated to mental health hospitals. With respect to disease 
burden data, the Global Burden of Disease Study 
collaborators have published country-level annual estimates 
of years lived with disability, years of life lost, and 
disability-adjusted life-years starting in 1993. We searched 
PubMed and publicly available reports identified by the 
authors, and consulted with additional expert sources, for 
studies comparing country-level government spending on 
mental, substance use, and neurological disorders, and 
suicide (combined or separately) in the Americas, with the 
related disease burden, using the search terms "mental 
health”, “mental disorders”, “substance use disorders”, 
“suicide”, “neurological disorders”, combined with 
“association”, “correlation” “imbalance”, OR “gap” and with 
“spending” OR “expenditures” AND “government” OR 
“public” AND “Americas” on July 1, 2016, for the past 
10 years, without language or field restrictions. We identified 
a few publications addressing different partial aspects of this 
issue, but no comprehensive analysis of the issue as a whole.
Added value of this study
We collated all country-level spending data available from these 
sources, identified the most recent datapoint for each country, 
and reviewed the peer-reviewed and grey literature to fill gaps 
in the data. With respect to burden, we extracted the raw Global 
Burden of Disease Study data (published in 2016), and we 
re-estimated the aggregate disease burden of mental, 
neurological, substance use disorders, and self-harm for the 
Americas. We present metrics to assess the imbalance between 
disease burden and spending on mental health, factoring in 
allocative efficiency. We used a log–log regression model to 
correlate the imbalance in efficiently allocated spending with 
real gross domestic product (GDP) per capita, identifying a 
significant and large negative association.
Implications of all the available evidence
In the Americas, the share of government mental health 
expenditure and allocative efficiency of spending rises as 
country-level, real GDP per-capita increases, compounding the 
scarcity of general health expenditure that affects lower-income 
countries. Better allocation of mental health expenditures is a 
priority in lower-income countries, given the high human and 
economic costs of untreated mental illness, including disability 
affecting working-age populations, out-of-pocket health 
spending, and decreased economic output.
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acute schizophrenia in the GBD severity distribution; 
d, proportion of government health spending allocated 
to mental health services; and e, proportion of 
government mental health spending allocated to 
psychiatric hospitals.
We then created two metrics of imbalance in mental 
health expenditures (f and g):
Metric f is a ratio of the proportion of disease burden to 
the proportion of health spending. Metric g includes in 
the denominator the fraction of spending available for 
com munity-based services after subtracting the fraction 
allocated to psychiatric hospitals to measure efficiently 
allocated spending. Additionally, we subtracted the 
burden of disease that cannot be directly and fully 
treated in the community from the numerator. 
Subtracting the disease burden of patients currently 
treated in psychiatric hospitals would produce an 
overestimate because most of them could and should be 
treated in the community. We there fore subtracted the 
disease burden due to acute schizo phrenia, which 
captures the fraction of the burden that arguably cannot 
be dealt with through community-based resources. The 
GBD framework includes a modelled distribution of 
health states by severity.24 For schizophrenia, it estimates 
that 63% of cases correspond to acute schizophrenia, 
with a disability weight of 0·778 (ranging from 0 
[representing health] to 1 [representing death]), and 37% 
of cases correspond to residual schizophrenia, carrying 
a disability weight of 0·588. Because years of life lost 
(YLLs) for schizophrenia captured by the GBD model 
are negligible, and because YLDs result from multi-
plying prevalence by disability weight, we estimated that 
69% of the disease burden of schizophrenia is 
attributable to the acute state.25,26
With these data, we considered three linear regression 
models, all in log–log form: (1) a regression of the 
proportion of total government health spending allocated 
to mental health services (metric d) on real GDP per 
capita (where c is country): 
(2) A regression of the proportion of mental health 
spending allocated to psychiatric hospitals (metric e) on 
real GDP per capita:
(3) A regression of imbalance in efficiently allocated 
spending (metric g) on real GDP per capita:
In these bivariate log–log regressions, variables on 
both sides are transformed by the natural logarithm 
function, implying that we can interpret the estimated 
slope coefficients (eg, β₁) as an estimate of elasticity.27,28 
In particular, in a log–log regression, the slope coefficient 
gives the approximate percentage point change in the 
left-hand side variable associated with a 1% change in the 
right-hand side variable. The approximation is exact for 
small changes in the right-hand side variable.
We also produced ranked bar-charts for both imbalance 
ratios:
Canada and USA
Latin Central America
Non-Latin Caribbean
South America
95% CIs
Bolivia
Saint Vincent and the Grenadines
British Virgin Islands
Antigua and Barbuda
MexicoHaiti
Guatemala
El Salvador
Dominican Republic
Costa Rica
Suriname USA
Barbados
CanadaUruguay
Jamaica
Saint Lucia
Trinidad and TobagoDominica ArgentinaPeru
Panama
Brazil
ChileBelize
Honduras
Guyana
Ecuador
Paraguay
Nicaragua
7·5 8·0 8·5 9·0 9·5 10·0 10·5 11·0
–1·5
–1·0
–0·5
0
0·5
1·0
1·5
2·0
Ln
 (%
 o
f g
ov
er
nm
en
t h
ea
lth
 sp
en
di
ng
 a
llo
ca
te
d 
to
 m
en
ta
l h
ea
lth
 se
rv
ice
s)
Ln (GDP 2015)
% allocated to mental health
0·2
2·0
4·0
6·0
8·6
Figure 1: Mental health spending vs GDP per capita
β₂=0·68 (95% CI 0·24–1·13). Linear model: Ln(% of government health expenditures spent on 
MNSS)=0·68 × Ln(GDP) + –5·6; R²=0·26; p=0·0036. MNSS=mental, neurological, and substance use disorders, 
and self-harm. GDP=gross domestic product.
a
f =
d
Ln (% of government health spending allocated to
mental health servicesc)=a1 + β1 Ln(GDPc) + ε1
Ln (% of mental health spending allocated to
psychiatric hospitalsc)=a2 + β2 Ln(GDPc) + ε2
Ln((%MNSS DALYs – 0·69 × schizophrenia DALYs) / 
(% mental health spending –[% mental health spending
× % psychiatric hospital spending]))c = a3 + β3 Ln(GDPc) + ε3
g=(a – b × c) / (d – d × e)
% of MNSS burden
% spent on mental health services
% of MNSS burden to be treated in the community
% of resources available for community services
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Models and figures were computed with Stata 14.2 and 
Tableau 10.1.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
Globally, in 2015, NCDs accounted for 60% of total 
DALYs, of which 12% corresponded to MNSS, whereas in 
the Americas they accounted for 78% of total DALYs, of 
which 19% corresponded to MNSS. The fraction of 
DALYs attribut able to MNSS varied among countries, 
ranging from 9% in Haiti to 23% in Canada (figure 1; 
appendix).
Globally, median spending on mental health stands at 
around 2% of total government health spending, while 
mental disorders account for 12% of total DALYs and 
35% of total YLDs as per our estimates updated to 
2015.2,5,6 Low-income countries spend around 0·5% of 
their health budget on mental health services, lower-
middle-income countries around 1·9%, upper-middle-
income countries 2·4%, and high-income countries 
5·1%.21 The median in the Americas is 2·4% ranging 
from 0·2% to 8·6%, while the regional disease burden 
attributable to MNSS comprises 19% of total DALYs and 
34% of total YLDs.
We calculated the natural log of mental health spending 
as a proportion of government health spending (metric d) 
and the natural log of real GDP per capita (figure 1) and 
found a positive association. We estimated regression 
model (1) and plotted its predicted values and 95% CIs 
(appendix). The estimated value of β₁ in this regression 
is 0·68 ([95% CI 0·24–1·13], p=0·0036), which is 
significantly different from zero at the 0·5% level (ie, if 
the true value of the slope parameter β were zero, the 
probability of seeing an estimated coefficient as large [in 
absolute value] as our estimate is smaller than 0·5%). 
Our model, however, does not establish the causal links 
that generate this association. The estimated value 
indicates that within the Americas, a country with a 
10% increase in real GDP per capita would allocate 
approximately a 6·8% larger proportion of its health 
expenditures to mental health. Note that this estimate is 
a percent increase in a fraction; for example, considering 
two countries, if the first country had a real GDP per 
capita of US$10 000 and the second of $11 000, if the first 
country allocated 10% of health expenditures to mental 
health, we would predict that the second country would 
allocate approximately 10·7%.
We ordered all countries by how disproportionate the 
burden of MNSS (DALYs) was in relation to expenditures 
(figure 2). Regional variation was high, with DALY 
burden ranging from 1·8 to 72·1 times expenditure. 
The median imbalance for American countries was 6·1 
(IQR 3·8–10·3)—ie, the proportion of total disease 
burden attributable to MNSS is six times the proportion 
of health funds allocated to mental health.
We next considered allocative efficiency of spending, 
defined as the distribution of resources to achieve the 
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See Online for appendix
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desirable combination of services and maximise societal 
health outcomes.29 Evidence indicates that MNSS services 
should aim to care for people in the community, 
providing services in primary care and general hospitals 
for common mental illnesses and community care 
for severely affected individuals.30 The proportion of 
spending that is not allocated to psychiatric hospitals can 
be considered a proxy for allocative efficiency, given the 
lack of evidence of effectiveness and reported association 
with iatrogenic practices.31–34 The median allocation to 
psychiatric hospitals in the Americas was 80% (52–92).
We calculated the log of the proportion of mental 
health spending allocated to psychiatric hospitals 
(metric e) and the log of real GDP per capita (figure 3) 
and found a negative association. Regression analysis 
reinforced this view. We estimated regression model (2) 
and found a significant negative estimate of –0·50 for 
β₂ ([95% CI –0·79 to –0·22], p=0·0012; appendix). We 
calculated the predicted values from the regression and 
95% CIs. This estimate indicates that a country with a 
10% increase in GDP would allocate approximately a 
5% lower proportion of mental health expenditures 
to psychiatric hospitals. Hence, countries with more 
developed economies not only spend a larger proportion 
of their health budget on mental health, but also allocate 
that increased proportion better than countries with less 
developed economies, where the lower proportion of 
mental health spending is compounded by lower overall 
health budgets to begin with and inefficient allocation, 
with psychiatric hospitals capturing most funds.
Considering the fraction of MNSS burden that should 
be cared for in the community divided by the spending 
not absorbed by psychiatric hospitals (metric g), we 
obtained a very different picture of the imbalance. 
To estimate the magnitude of the compounded imbalance 
in spending, we ordered countries from the lowest ratio 
of burden over efficiently allocated spending (figure 4). 
The imbalance ratio varied by two orders of magnitude, 
from the burden being three times spending in the USA 
and Canada to 435 times spending in Haiti, and more 
than 100 times in a third of American countries.
We calculated the log of the imbalance ratio and the log 
of real GDP per capita (figure 5). A negative association 
was shown and was corroborated by the estimation of 
regression (3). The estimated value of β₃ was –1·38 
([95% CI –1·97 to –0·78], p=0·0001) and was significantly 
different from zero (appendix). The estimated coefficient 
suggests that a country with a 10% increase in GDP will 
have approximately a 14% lower imbalance ratio for 
mental health expenditures.
Given the limitations of the available data, we did 
additional analyses to check that our results were not 
unduly influenced by potential outliers or methodological 
assumptions, or contingent on the functional form 
chosen for the variables. First, inspection of figure 5 
raised the possibility that Haiti, Canada, and the USA 
might be outliers unduly influ encing our results. Hence, 
we re-ran the analyses excluding these three countries 
for all three models (appendix). The results are 
quantitatively similar to those presented above. However, 
the estimated coefficient β₂ in the new regression (2) was 
not significant, though it was still negative.
Second, we used the natural log transformed variables 
to facilitate interpretation of the results in terms of 
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elasticities—ie, proportionate changes in response 
variables (metrics d, e, and g) to proportionate changes in 
real GDP per capita. To confirm that these results were 
not contingent on variable transformation, we also ran 
our three models on the non-transformed variables 
(appendix). The results were qualitatively identical to 
those reported above.
Finally, we ran our model regressing imbalance on 
GDP, but excluded dementia, suicide, and our estimation 
for somatic pain syndrome from the burden calcu-
lations—ie, we used the standard GBD estimates. The 
results were quantitatively similar to figure 5: the esti-
mated coefficient was similar and significantly different 
from zero (β₃ –1·5; r² 0·53; p=0·0001).
Discussion
MNSS spending in the Americas is low compared with 
the associated disease burden and is mostly captured 
by psychiatric hospitals; the resulting imbalance in 
efficiently allocated spending is negatively associated 
with real GDP per capita.
WHO recommends that health spending should be 
proportionate to burden as a general rule for all health 
conditions, and that there should be parity between 
physical and mental aspects of health care.30,35 To measure 
the burden of mental health disorders, we used DALYs 
with an expanded definition of MNSS taking into account 
specific neuro logical conditions, self-harm, and a fraction 
of painful syndromes.6 In a Comment36 regarding our 
model, the GBD collaborators agreed on the need to 
include excess death due to mental illness and burden 
resulting from neurological disorders, personality 
disorders, and somatoform disorders. However, they 
found the existing evidence insufficient and, therefore, 
attributed 0% of the burden resulting from painful 
syndromes and self-harm to MNSS and 0% of total YLLs 
to mental disorders. These attributions lack face validity 
and might have deleterious policy consequences, so we 
find our approach preferable. However, we acknowledge 
its limitations: the non-zero fraction of pain disorders 
imputed to MNSS is based on our review of the evidence 
and not on primary data, which is unavailable;6,37 further, 
our approach does not distinguish the small fraction 
of suicide that should not be included in MNSS 
(eg, euthanasia).
Selection and information bias are important concerns 
in ecological studies. Selection bias affects ecological 
studies with a poorly defined population of interest or 
sampling method. The 35 countries in the WHO Region 
of the Americas constituted our population of interest. 
Our aim was to achieve a full population sample, but we 
were unable to obtain sufficient data for five countries; 
therefore, our sample covers 87% of the population of 
interest, which might limit generalisability to the full set 
of countries. A limitation to our conclusions emerges 
from the nature of the expenditure data, which are self-
reported by ministries to WHO and are susceptible to 
errors and inconsistencies leading to information bias. 
For example, potentially a substantial amount of  resources 
allocated to dementia care or suicide pre vention, and 
MNSS services delivered through primary care or non-
health sectors, might be reported by some countries but 
not others. However, no alternative source of comparable 
comprehensiveness and quality is available.38,39 Further, if 
we assume that these channels of spending are expected 
to be higher in countries with higher GDP per capita, the 
result would be a more pronounced negative association 
between GDP and imbalance, making our findings 
conservative. Another caveat should be highlighted: our 
estimations do not account for private spending, which 
is a substantial source of mental health funding. We will 
address this issue and its potential consequences on 
health inequalities below. A final caveat results from 
treating countries for which key datapoints were not 
available as missing at random and therefore dropping 
them from the analysis. Considering the culture, 
population, economic arrangements, and health systems 
of the five countries dropped, we see that Colombia and 
Cuba are quite different within themselves and compared 
with the other three countries, so we posit that our 
missing at random assumption holds for them. Bahamas, 
Grenada, and St Kitts and Nevis are all small Caribbean 
island nations with more homogeneous characteristics 
(English or Creole-speaking smaller populations, tourism 
and agriculture-based economies), so our conclusions 
might not be applicable to this type of American country.
An important discussion is what the adequate ratio of 
burden to spending should be. A ratio of one would 
imply the assumption of equivalent cost-effectiveness of 
interventions across health sectors, which would not be 
grounded on evidence despite the well established cost-
effectiveness of a broad range of mental health inter-
ventions.40 To provide a benchmark, the National Health 
Service (NHS) in England can function as a real-world 
comparator of efficiently allocated mental health 
spending. Despite recent decreases in funding,41 NHS 
England has achieved notable outcomes in terms 
of providing evidence-based interventions, universal 
coverage, integration in primary care, and community 
rehabilitation—all leading to comparatively high user 
satisfaction.42 Additionally, because private spending is 
minimal, the ratio actually reflects the imbalance. The 
disease burden of MNSS in England represents 20% of 
total DALYs, and spending was estimated at 13% of 
health expenditures; therefore, our real-world comparator 
of imbalance would be 1·5:1.41 Our first metric of the 
imbalance in the Americas yielded a range from 1·8:1 to 
72·1:1, but fails to capture the compounding effect of 
misallocation. Our second metric provides a more 
accurate picture of the imbalance in spending by 
factoring in allocative efficiency: we found that the 
regional median imbalance between mental health 
burden and spending was 32:1, with a range of between 
3:1 and 435:1. The gap in spending is significantly and 
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inversely associated with real GDP per capita, 
disproportionately affecting lower-income countries 
(appendix).
This observed imbalance potentially results in an 
increasing treatment gap in poorer countries and 
increased private spending on mental health services, 
out-of-pocket spending in particular. For example, the 
3:1 imbalance between disease burden and efficiently 
allocated spending affecting Canada and the USA is 
consistent with findings that establish the treatment gap 
for major depressive disorder in high-income countries 
to be 5:1; only 22·4% of patients received minimally 
adequate treatment in high-income countries (the 
remainder did not receive treatment), 26·6% (4:1) 
specifically in the USA.43 In low-income or lower-middle-
income countries, the gap was estimated at 27:1; only 
4·7% of people in need received minimally adequate 
services. In Peru, less than one person received minimally 
adequate treatment for every 100 people with a valid 
diagnosis of major depressive disorder.43 These data are in 
line with our findings, which indicate that the USA and 
Canada have the lowest imbalance at 3:1, Peru has one of 
the largest gaps in the continent with a 312:1 imbalance in 
burden relative to efficiently allocated spending, and the 
27:1 gap43 in low-income and lower-middle-income 
countries is consistent with our American median of 32:1. 
Our results merit further study as to whether the 
imbalance in government funding in poorer countries is 
being covered by increased out-of-pocket spending by 
people living in these countries, therefore, further 
compounding the burden on the poor.
Mental health is increasingly acknowledged as a global 
health and economic development priority, as articulated 
in the Sustainable Development Goals referring to 
mental health and wellbeing.44–49 However, the proportion 
of funds spent on mental health tends to be low and 
inefficiently allocated, with the least effective and cost-
effective interventions receiving the largest share, 
particularly in low-income and middle-income countries. 
In the Americas, MNSS are the largest subgroup cause 
of disease burden, both when considering disability 
alone and combined with mortality; they comprise a 
third of total YLDs and a fifth of total DALYs. Governments 
of low-income and middle-income countries, in parti-
cular, must adjust the allocation of their mental health 
expenditures. Instead of allocating most funds to 
specialised hospitals, countries should prioritise mental 
health services integrated into primary care and delivered 
in the community—a strategy that would target not only 
the direct burden resulting from MNSS but also the 
excess mortality due to treatable causes, which are 
ineffectively cared for because of stigma, insufficient 
community support, and poorly integrated health 
services.50,51
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